Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
National Center for Complementary and Alternative Medicine (NCCAM) |
---|---|
Information provided by: | National Center for Complementary and Alternative Medicine (NCCAM) |
ClinicalTrials.gov Identifier: | NCT00010920 |
Preventing dementia is an important goal for our aging population. This proposal is an initial 42 months study of the effect of standardized ginkgo biloba extract (GBE) on preventing or delaying cognitive decline in people age 85 years or older (the oldest old). The study focuses on the oldest old who present a distinct advantage for primary prevention studies because of their particularly high risk for developing mild cognitive impairment (MCI), a precursor to dementia. Because this is a population that has previously been out of the mainstream for use of alternative medicine, the safety of GBE in this age group will also be tested in this study. The study is randomized, placebo controlled and double blind. Approximately 200 elderly cognitively healthy subjects will be enrolled and followed for detection of conversion to MCI. This pilot study is viewed as a necessary first step in order to demonstrate that GBE, an alternative or complementary therapy, has a disease modifying effect on the brain, distinct from a symptomatic effect. The study will test the feasibility of the randomized start design, a trial design proposed as a method for discerning brain- or disease- modifying from symptomatic effects. The magnitude of biological effect of the treatments will also be assessed with volumetric quantitative MRI, a complementary means of confirming whether there is a brain modifying effect (measured as a decrease in brain volume loss with treatment). Peripheral markers of oxidation status will measure possible anti-oxidant effects of GBE.
Condition | Intervention | Phase |
---|---|---|
Dementia Memory Disorders |
Drug: Ginkgo Biloba Extract |
Phase III |
Study Type: | Interventional |
Study Design: | Prevention, Randomized, Double-Blind, Placebo Control |
Official Title: | Preventing Cognitive Decline With Alternative Therapies |
Ages Eligible for Study: | 85 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
United States, Oregon | |
Oregon Health Sciences University/Neurology | |
Portland, Oregon, United States, 97201 |
Principal Investigator: | Dr. Jeffrey Kaye | Oregon Health and Science University |
Study ID Numbers: | P50 AT000066-01P2, P50 AT000066-01 |
Study First Received: | February 2, 2001 |
Last Updated: | August 17, 2006 |
ClinicalTrials.gov Identifier: | NCT00010920 |
Health Authority: | United States: Federal Government |
Signs and Symptoms Delirium, Dementia, Amnestic, Cognitive Disorders Mental Disorders Central Nervous System Diseases Neurologic Manifestations Brain Diseases |
Dementia Neurobehavioral Manifestations Memory Disorders Cognition Disorders Delirium |
Nervous System Diseases |